Hmgn. Patient population for trial . Anyone see 75 % DSMC report . They may skipped theirs as well . Not sure , Don’t follow them that close . No critical in their trial. . Unless they progressed from trail entry .

• 78 percent of trial participants on either remdesivir or dexamethasone (or other steroids) or both (across both arms of the study)
• 65 percent of trial participants with oxygen saturation ≤ 94 percent or on low-flow oxygen support
• 35 percent of trial participants on high-flow oxygen or non-invasive positive pressure ventilation at
time of enrollment
• 45 percent of trial participants were 65 years of age or older
• 50 percent of trial participants from diverse populations
• No serious adverse events have been attributed to lenzilumab
• These findings apply across both arms of the study